[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f4pTh1VGqzac0rvMs6tdVs8dGO_QG-OiW5ZFRJssu_k4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":34,"rows":41},"Institute for Clinical and Experimental Medicine",[4],60,false,17,5,14766,0,42,[14,17,19,21,24,26,29,31],{"name":15,"count":16},"Heart Failure",6,{"name":18,"count":9},"Insulin Resistance",{"name":20,"count":9},"Kidney Transplantation",{"name":22,"count":23},"Gastroparesis",4,{"name":25,"count":23},"Type 2 Diabetes",{"name":27,"count":28},"Atrial Fibrillation",3,{"name":30,"count":28},"Diabetes Mellitus, Type 1",{"name":32,"count":28},"Cardiovascular Diseases",[],[35,36,37,38,39,40],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[42,71,89,115,133,159,184,202,228,254,297,339,366,384,410,428,453,479,507,525,543,561,592],{"intervention":43,"totalTrials":44,"cells":45},"IGlarLixi",1,{"EARLY_PHASE1":46,"PHASE1":48,"PHASE2":50,"PHASE3":52,"PHASE4":54,"NA":69},{"trials":47,"activeCount":11},[],{"trials":49,"activeCount":11},[],{"trials":51,"activeCount":11},[],{"trials":53,"activeCount":11},[],{"trials":55,"activeCount":11},[56],{"nctId":57,"briefTitle":58,"status":59,"phases":60,"primaryCompletion":61,"completion":62,"start":63,"enrollment":64,"conditions":65,"interventions":67},"NCT04945070","INSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixi","UNKNOWN",[39],"2023-01","2023-06","2021-07",96,[66],"Type 2 Diabetes Treated With Insulin",[43,68],"MDI - Multiple dose insulin",{"trials":70,"activeCount":11},[],{"intervention":68,"totalTrials":44,"cells":72},{"EARLY_PHASE1":73,"PHASE1":75,"PHASE2":77,"PHASE3":79,"PHASE4":81,"NA":87},{"trials":74,"activeCount":11},[],{"trials":76,"activeCount":11},[],{"trials":78,"activeCount":11},[],{"trials":80,"activeCount":11},[],{"trials":82,"activeCount":11},[83],{"nctId":57,"briefTitle":58,"status":59,"phases":84,"primaryCompletion":61,"completion":62,"start":63,"enrollment":64,"conditions":85,"interventions":86},[39],[66],[43,68],{"trials":88,"activeCount":11},[],{"intervention":90,"totalTrials":44,"cells":91},"Sirolimus Oral Product",{"EARLY_PHASE1":92,"PHASE1":94,"PHASE2":96,"PHASE3":98,"PHASE4":100,"NA":113},{"trials":93,"activeCount":11},[],{"trials":95,"activeCount":11},[],{"trials":97,"activeCount":11},[],{"trials":99,"activeCount":11},[],{"trials":101,"activeCount":11},[102],{"nctId":103,"briefTitle":104,"status":105,"phases":106,"primaryCompletion":107,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":111},"NCT03582878","Sirolimus vs Mycophenolate With Tacrolimus in Simultaneous Pancreas and Kidney Transplantation","COMPLETED",[39],"2019-01-01","2004-01-01",238,[30],[90,112],"Mycophenolate Mofetil",{"trials":114,"activeCount":11},[],{"intervention":112,"totalTrials":44,"cells":116},{"EARLY_PHASE1":117,"PHASE1":119,"PHASE2":121,"PHASE3":123,"PHASE4":125,"NA":131},{"trials":118,"activeCount":11},[],{"trials":120,"activeCount":11},[],{"trials":122,"activeCount":11},[],{"trials":124,"activeCount":11},[],{"trials":126,"activeCount":11},[127],{"nctId":103,"briefTitle":104,"status":105,"phases":128,"primaryCompletion":107,"completion":107,"start":108,"enrollment":109,"conditions":129,"interventions":130},[39],[30],[90,112],{"trials":132,"activeCount":11},[],{"intervention":134,"totalTrials":44,"cells":135},"Alirocumab",{"EARLY_PHASE1":136,"PHASE1":138,"PHASE2":140,"PHASE3":142,"PHASE4":144,"NA":157},{"trials":137,"activeCount":11},[],{"trials":139,"activeCount":11},[],{"trials":141,"activeCount":11},[],{"trials":143,"activeCount":11},[],{"trials":145,"activeCount":11},[146],{"nctId":147,"briefTitle":148,"status":59,"phases":149,"primaryCompletion":150,"completion":151,"start":152,"enrollment":153,"conditions":154,"interventions":156},"NCT04193306","Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant Recipients",[39],"2025-05","2025-07","2019-11-18",126,[155],"Cardiac Allograft Vasculopathy",[134],{"trials":158,"activeCount":11},[],{"intervention":160,"totalTrials":44,"cells":161},"Privigen",{"EARLY_PHASE1":162,"PHASE1":164,"PHASE2":166,"PHASE3":168,"PHASE4":180,"NA":182},{"trials":163,"activeCount":11},[],{"trials":165,"activeCount":11},[],{"trials":167,"activeCount":11},[],{"trials":169,"activeCount":11},[170],{"nctId":171,"briefTitle":172,"status":105,"phases":173,"primaryCompletion":174,"completion":175,"start":176,"enrollment":8,"conditions":177,"interventions":178},"NCT04302805","rATG Versus rATG Combined With Intravenous Immunoglobulin (IVIG) Induction Immunosuppression in HLA Incompatible Transplantation (INHIBIT)",[38],"2024-04-15","2024-06-15","2020-07-27",[20],[160,179],"Thymoglobulin",{"trials":181,"activeCount":11},[],{"trials":183,"activeCount":11},[],{"intervention":179,"totalTrials":44,"cells":185},{"EARLY_PHASE1":186,"PHASE1":188,"PHASE2":190,"PHASE3":192,"PHASE4":198,"NA":200},{"trials":187,"activeCount":11},[],{"trials":189,"activeCount":11},[],{"trials":191,"activeCount":11},[],{"trials":193,"activeCount":11},[194],{"nctId":171,"briefTitle":172,"status":105,"phases":195,"primaryCompletion":174,"completion":175,"start":176,"enrollment":8,"conditions":196,"interventions":197},[38],[20],[160,179],{"trials":199,"activeCount":11},[],{"trials":201,"activeCount":11},[],{"intervention":203,"totalTrials":44,"cells":204},"Metformini hydrochloridum",{"EARLY_PHASE1":205,"PHASE1":207,"PHASE2":209,"PHASE3":211,"PHASE4":224,"NA":226},{"trials":206,"activeCount":11},[],{"trials":208,"activeCount":11},[],{"trials":210,"activeCount":11},[],{"trials":212,"activeCount":11},[213],{"nctId":214,"briefTitle":215,"status":105,"phases":216,"primaryCompletion":217,"completion":218,"start":219,"enrollment":220,"conditions":221,"interventions":223},"NCT01690091","Cardioprotective and Metabolic Effects of Metformin in Patients With Heart Failure and Diabetes",[37,38],"2016-05","2016-12","2012-11",40,[18,222],"Chronic Heart Failure",[203],{"trials":225,"activeCount":11},[],{"trials":227,"activeCount":11},[],{"intervention":229,"totalTrials":44,"cells":230},"Mesalazine 4G Enema",{"EARLY_PHASE1":231,"PHASE1":233,"PHASE2":235,"PHASE3":248,"PHASE4":250,"NA":252},{"trials":232,"activeCount":11},[],{"trials":234,"activeCount":11},[],{"trials":236,"activeCount":11},[237],{"nctId":238,"briefTitle":239,"status":105,"phases":240,"primaryCompletion":241,"completion":242,"start":243,"enrollment":244,"conditions":245,"interventions":247},"NCT03104036","Faecal Bacteriotherapy for Ulcerative Colitis",[37],"2021-01-30","2021-06-30","2017-06-19",61,[246],"Ulcerative Colitis",[229],{"trials":249,"activeCount":11},[],{"trials":251,"activeCount":11},[],{"trials":253,"activeCount":11},[],{"intervention":255,"totalTrials":28,"cells":256},"Warfarin",{"EARLY_PHASE1":257,"PHASE1":259,"PHASE2":261,"PHASE3":263,"PHASE4":265,"NA":267},{"trials":258,"activeCount":11},[],{"trials":260,"activeCount":11},[],{"trials":262,"activeCount":11},[],{"trials":264,"activeCount":11},[],{"trials":266,"activeCount":11},[],{"trials":268,"activeCount":11},[269,279,288],{"nctId":270,"briefTitle":271,"status":59,"phases":272,"primaryCompletion":273,"completion":274,"start":275,"enrollment":276,"conditions":277,"interventions":278},"NCT03078374","MAGENTUM 1 HeartMate 3 LVAS: A Single Center Prospective Controlled Study (MAGENTUM 1)",[40],"2022-01","2022-10","2017-01-11",15,[15,32],[255],{"nctId":280,"briefTitle":281,"status":59,"phases":282,"primaryCompletion":283,"completion":283,"start":284,"enrollment":285,"conditions":286,"interventions":287},"NCT03781258","Anti-thrombotic Monotherapy in HeartMate 3 Left Ventricular Assist System (LVAS)",[40],"2021-12-31","2018-11-23",20,[15,32],[255],{"nctId":289,"briefTitle":290,"status":59,"phases":291,"primaryCompletion":292,"completion":292,"start":293,"enrollment":294,"conditions":295,"interventions":296},"NCT03704220","Anti-thrombotic Monotherapy With the HeartMate 3 LVAS",[40],"2021-12","2018-08-16",10,[15,32],[255],{"intervention":298,"totalTrials":299,"cells":300},"Tacrolimus",2,{"EARLY_PHASE1":301,"PHASE1":303,"PHASE2":305,"PHASE3":307,"PHASE4":324,"NA":326},{"trials":302,"activeCount":11},[],{"trials":304,"activeCount":11},[],{"trials":306,"activeCount":11},[],{"trials":308,"activeCount":11},[309],{"nctId":310,"briefTitle":311,"status":59,"phases":312,"primaryCompletion":313,"completion":314,"start":315,"enrollment":285,"conditions":316,"interventions":323},"NCT03277430","Uterus Transplantation From Live Donors and From Deceased Donors - Clinical Study",[38],"2020-12-31","2025-12-31","2015-10-09",[317,318,319,320,321,322],"Mayer Rokitansky Kuster Hauser Syndrome","Mullerian Aplasia","Uterus; Absence, Congenital","Infertility, Female","Uterus Absence, Acquired","Absolute Uterine Factor Infertility",[298],{"trials":325,"activeCount":11},[],{"trials":327,"activeCount":11},[328],{"nctId":329,"briefTitle":330,"status":105,"phases":331,"primaryCompletion":332,"completion":332,"start":333,"enrollment":285,"conditions":334,"interventions":335},"NCT02711202","Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation",[40],"2009-03","2007-01",[20],[336,337,338,298],"MabCampath,","Remicade","Sirolimus",{"intervention":340,"totalTrials":44,"cells":341},"Intensive heart rate control with landiolol",{"EARLY_PHASE1":342,"PHASE1":344,"PHASE2":346,"PHASE3":348,"PHASE4":350,"NA":352},{"trials":343,"activeCount":11},[],{"trials":345,"activeCount":11},[],{"trials":347,"activeCount":11},[],{"trials":349,"activeCount":11},[],{"trials":351,"activeCount":11},[],{"trials":353,"activeCount":11},[354],{"nctId":355,"briefTitle":356,"status":59,"phases":357,"primaryCompletion":358,"completion":358,"start":359,"enrollment":220,"conditions":360,"interventions":364},"NCT04694092","Landiolol for Rate Control in Decompensated Heart Failure Due to Atrial Fibrillation",[40],"2023-12-31","2020-11-05",[27,361,362,363],"Atrial Fibrillation Rapid","Acute Heart Failure","Left Ventricular Dysfunction",[340,365],"Standard approach to heart rate control",{"intervention":365,"totalTrials":44,"cells":367},{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":372,"PHASE3":374,"PHASE4":376,"NA":378},{"trials":369,"activeCount":11},[],{"trials":371,"activeCount":11},[],{"trials":373,"activeCount":11},[],{"trials":375,"activeCount":11},[],{"trials":377,"activeCount":11},[],{"trials":379,"activeCount":11},[380],{"nctId":355,"briefTitle":356,"status":59,"phases":381,"primaryCompletion":358,"completion":358,"start":359,"enrollment":220,"conditions":382,"interventions":383},[40],[27,361,362,363],[340,365],{"intervention":385,"totalTrials":44,"cells":386},"Losartan",{"EARLY_PHASE1":387,"PHASE1":389,"PHASE2":391,"PHASE3":393,"PHASE4":395,"NA":397},{"trials":388,"activeCount":11},[],{"trials":390,"activeCount":11},[],{"trials":392,"activeCount":11},[],{"trials":394,"activeCount":11},[],{"trials":396,"activeCount":11},[],{"trials":398,"activeCount":11},[399],{"nctId":400,"briefTitle":401,"status":105,"phases":402,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":407,"interventions":408},"NCT01011062","Effect of Angiotensin Receptor Blockade on Insulin Resistance and Adipose Tissue Cytokines in Type 2 Diabetes",[40],"2007-10","2009-08","2004-01",23,[18,25],[385,409],"Saline",{"intervention":409,"totalTrials":44,"cells":411},{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":416,"PHASE3":418,"PHASE4":420,"NA":422},{"trials":413,"activeCount":11},[],{"trials":415,"activeCount":11},[],{"trials":417,"activeCount":11},[],{"trials":419,"activeCount":11},[],{"trials":421,"activeCount":11},[],{"trials":423,"activeCount":11},[424],{"nctId":400,"briefTitle":401,"status":105,"phases":425,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":426,"interventions":427},[40],[18,25],[385,409],{"intervention":429,"totalTrials":44,"cells":430},"Apixaban",{"EARLY_PHASE1":431,"PHASE1":433,"PHASE2":435,"PHASE3":437,"PHASE4":439,"NA":441},{"trials":432,"activeCount":11},[],{"trials":434,"activeCount":11},[],{"trials":436,"activeCount":11},[],{"trials":438,"activeCount":11},[],{"trials":440,"activeCount":11},[],{"trials":442,"activeCount":11},[443],{"nctId":444,"briefTitle":445,"status":105,"phases":446,"primaryCompletion":447,"completion":447,"start":448,"enrollment":449,"conditions":450,"interventions":452},"NCT04974684","DOT HeartMate 3 Study",[40],"2024-03-01","2022-04-01",45,[451],"LVAD (Left Ventricular Assist Device) Thrombosis",[429],{"intervention":454,"totalTrials":44,"cells":455},"Antirejection therapy",{"EARLY_PHASE1":456,"PHASE1":458,"PHASE2":460,"PHASE3":462,"PHASE4":464,"NA":466},{"trials":457,"activeCount":11},[],{"trials":459,"activeCount":11},[],{"trials":461,"activeCount":11},[],{"trials":463,"activeCount":11},[],{"trials":465,"activeCount":11},[],{"trials":467,"activeCount":11},[468],{"nctId":469,"briefTitle":470,"status":105,"phases":471,"primaryCompletion":472,"completion":473,"start":474,"enrollment":475,"conditions":476,"interventions":478},"NCT06476717","Donor-derived Cell-free DNA in Kidney Transplant Recipients",[],"2024-05-12","2024-05-20","2021-10-21",143,[20,477],"Acute Rejection of Renal Transplant",[454],{"intervention":480,"totalTrials":44,"cells":481},"Control group",{"EARLY_PHASE1":482,"PHASE1":484,"PHASE2":486,"PHASE3":488,"PHASE4":490,"NA":492},{"trials":483,"activeCount":11},[],{"trials":485,"activeCount":11},[],{"trials":487,"activeCount":11},[],{"trials":489,"activeCount":11},[],{"trials":491,"activeCount":11},[],{"trials":493,"activeCount":11},[494],{"nctId":495,"briefTitle":496,"status":59,"phases":497,"primaryCompletion":498,"completion":499,"start":500,"enrollment":501,"conditions":502,"interventions":506},"NCT05326113","The Effect of Physiotherapy on Post POEM Reflux",[40],"2024-08-18","2025-01-18","2021-10-31",30,[503,504,505],"Reflux, Gastroesophageal","Achalasia","Esophagitis",[480],{"intervention":336,"totalTrials":44,"cells":508},{"EARLY_PHASE1":509,"PHASE1":511,"PHASE2":513,"PHASE3":515,"PHASE4":517,"NA":519},{"trials":510,"activeCount":11},[],{"trials":512,"activeCount":11},[],{"trials":514,"activeCount":11},[],{"trials":516,"activeCount":11},[],{"trials":518,"activeCount":11},[],{"trials":520,"activeCount":11},[521],{"nctId":329,"briefTitle":330,"status":105,"phases":522,"primaryCompletion":332,"completion":332,"start":333,"enrollment":285,"conditions":523,"interventions":524},[40],[20],[336,337,338,298],{"intervention":337,"totalTrials":44,"cells":526},{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":531,"PHASE3":533,"PHASE4":535,"NA":537},{"trials":528,"activeCount":11},[],{"trials":530,"activeCount":11},[],{"trials":532,"activeCount":11},[],{"trials":534,"activeCount":11},[],{"trials":536,"activeCount":11},[],{"trials":538,"activeCount":11},[539],{"nctId":329,"briefTitle":330,"status":105,"phases":540,"primaryCompletion":332,"completion":332,"start":333,"enrollment":285,"conditions":541,"interventions":542},[40],[20],[336,337,338,298],{"intervention":338,"totalTrials":44,"cells":544},{"EARLY_PHASE1":545,"PHASE1":547,"PHASE2":549,"PHASE3":551,"PHASE4":553,"NA":555},{"trials":546,"activeCount":11},[],{"trials":548,"activeCount":11},[],{"trials":550,"activeCount":11},[],{"trials":552,"activeCount":11},[],{"trials":554,"activeCount":11},[],{"trials":556,"activeCount":11},[557],{"nctId":329,"briefTitle":330,"status":105,"phases":558,"primaryCompletion":332,"completion":332,"start":333,"enrollment":285,"conditions":559,"interventions":560},[40],[20],[336,337,338,298],{"intervention":562,"totalTrials":44,"cells":563},"Booster dose of mRNA vaccine",{"EARLY_PHASE1":564,"PHASE1":566,"PHASE2":568,"PHASE3":570,"PHASE4":572,"NA":574},{"trials":565,"activeCount":11},[],{"trials":567,"activeCount":11},[],{"trials":569,"activeCount":11},[],{"trials":571,"activeCount":11},[],{"trials":573,"activeCount":11},[],{"trials":575,"activeCount":11},[576],{"nctId":577,"briefTitle":578,"status":59,"phases":579,"primaryCompletion":580,"completion":581,"start":582,"enrollment":583,"conditions":584,"interventions":591},"NCT05483725","Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.",[],"2024-12-04","2024-12-31","2021-10-04",108,[585,586,587,588,589,590],"Kidney Diseases","Kidney Transplant; Complications","COVID-19","Vaccine Adverse Reaction","Rejection Acute Renal","Rejection Chronic Renal",[562],{"intervention":593,"totalTrials":44,"cells":594},"Polyclonal anti-T-cell antibodies",{"EARLY_PHASE1":595,"PHASE1":597,"PHASE2":599,"PHASE3":601,"PHASE4":603,"NA":605},{"trials":596,"activeCount":11},[],{"trials":598,"activeCount":11},[],{"trials":600,"activeCount":11},[],{"trials":602,"activeCount":11},[],{"trials":604,"activeCount":11},[],{"trials":606,"activeCount":11},[607],{"nctId":608,"briefTitle":609,"status":59,"phases":610,"completion":611,"start":612,"enrollment":613,"conditions":614,"interventions":615},"NCT00190502","Polyclonal Anti-T-Lymphocyte Globulin (ATG) in Type 1 Diabetes",[40],"2007-12","2000-11",28,[30],[593]]